Recurrent Clostridium difficile Infection and Proton-Pump Inhibitors

PPI use during treatment for CDI was associated with excess risk for infection recurrence.

The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade, and the relapse rate for this infection can be high. Proton-pump inhibitor (PPI) use has been associated with excess risk for infections such as CDI.

To determine whether PPI use is associated with risk for recurrent CDI, investigators conducted a retrospective study of patients identified from the New England Veterans Healthcare System from October 2003 through September 2008. A total of 1166 patients (97% male; median age, 74) with CDI documented by toxin assays were treated with metronidazole or vancomycin. Of this cohort, 527 (45.2%) received PPIs during initial treatment (within 14 days of CDI diagnosis), and most of these patients (82.…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Recurrent Clostridium difficile Infection and Proton-Pump Inhibitors

Topics

Reviewing Author